Cagrilintide prices

FROM PEPTIDES CALCULATOR

About Cagrilintide

Source profile reviewed 2026-10-01 · Imported 2026-10-22. Read the full compound profile

Cagrilintide, developed by Novo Nordisk under the code AM833, is a long-acting analog of amylin, the hormone the pancreas releases alongside insulin to signal fullness. A C20 fatty diacid attached through a glutamate linker extends its action to about a week, so it is given as a once-weekly subcutaneous injection. On its own it produced 6.0% to 10.8% weight loss at 26 weeks in a phase 2 dose-finding trial and 11.8% at 68 weeks in a phase 3 comparison arm. Its main development path is as half of CagriSema, a fixed-dose combination with semaglutide in one pen, which produced 22.7% weight loss at 68 weeks in adults without diabetes and 15.7% in adults with type 2 diabetes on the adherence-based analysis. Neither cagrilintide alone nor CagriSema is approved, so there is no label and no approved dosing schedule.

Formula

C194 H312 N54 O59 S2

Molar mass

4,409 g/mol

CAS number

1415456-99-3

Amino acids

38

Research evidence described in the source

Limitations noted in the source

• Combination-trial results cannot be attributed to cagrilintide alone.
• The calculator preset is not a substitute for the escalation used in trials.
• A calculator preset is a recorded research convention, not a recommendation or evidence of clinical benefit.
• Identity, purity, sterility, and stability can vary substantially outside regulated manufacturing.

Background is reproduced from Peptides Calculator with attribution. The source describes compound-level research. It does not evaluate the identity, quality or suitability of a listed supplier’s product or batch.